Neoleukin Therapeutics Stock Shares Outstanding
NLTXDelisted Stock | USD 0.69 0.01 1.43% |
Neoleukin Therapeutics fundamentals help investors to digest information that contributes to Neoleukin Therapeutics' financial success or failures. It also enables traders to predict the movement of Neoleukin Stock. The fundamental analysis module provides a way to measure Neoleukin Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Neoleukin Therapeutics stock.
Neoleukin |
Neoleukin Therapeutics Company Shares Outstanding Analysis
Neoleukin Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Neoleukin Therapeutics Shares Outstanding | 2.35 M |
Most of Neoleukin Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Neoleukin Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Neoleukin Therapeutics has 2.35 M of shares currently outstending. This is 98.7% lower than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The shares outstanding for all United States stocks is 99.59% higher than that of the company.
Neoleukin Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Neoleukin Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Neoleukin Therapeutics could also be used in its relative valuation, which is a method of valuing Neoleukin Therapeutics by comparing valuation metrics of similar companies.Neoleukin Therapeutics is currently under evaluation in shares outstanding category among its peers.
Neoleukin Fundamentals
Return On Equity | -0.38 | |||
Return On Asset | -0.19 | |||
Current Valuation | (35.02 M) | |||
Shares Outstanding | 2.35 M | |||
Shares Owned By Insiders | 16.46 % | |||
Shares Owned By Institutions | 45.58 % | |||
Number Of Shares Shorted | 26.4 K | |||
Price To Earning | (4.60) X | |||
Price To Book | 0.44 X | |||
EBITDA | (56.48 M) | |||
Net Income | (57.56 M) | |||
Cash And Equivalents | 116.46 M | |||
Cash Per Share | 2.73 X | |||
Total Debt | 12.07 M | |||
Debt To Equity | 0.11 % | |||
Current Ratio | 12.78 X | |||
Book Value Per Share | 34.18 X | |||
Cash Flow From Operations | (45.61 M) | |||
Short Ratio | 1.70 X | |||
Earnings Per Share | (12.28) X | |||
Price To Earnings To Growth | (0.03) X | |||
Target Price | 1.5 | |||
Beta | 1.1 | |||
Market Capitalization | 8.2 M | |||
Total Asset | 115.95 M | |||
Retained Earnings | (451.06 M) | |||
Working Capital | 88.07 M | |||
Current Asset | 289 K | |||
Current Liabilities | 1.02 M | |||
Z Score | -5.73 | |||
Net Asset | 115.95 M |
About Neoleukin Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Neoleukin Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neoleukin Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neoleukin Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Other Consideration for investing in Neoleukin Stock
If you are still planning to invest in Neoleukin Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neoleukin Therapeutics' history and understand the potential risks before investing.
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
CEOs Directory Screen CEOs from public companies around the world | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |